News | Radiation Therapy | January 16, 2026

The Elekta Evo CT-Linac now has 510(k) clearance from the U.S. Food and Drug Administration.


Jan. 16, 2026 — Elekta has announced that its Elekta Evo* CT-Linac has received 510(k) clearance from the U.S. Food and Drug Administration (FDA). This milestone makes the system available to radiation oncology professionals in the United States.

When delivering radiation therapy, clinicians require high-quality images that allow them to identify tumors and organs-at-risk. Evo addresses this with Iris high-definition, AI-enhanced imaging, which allows physicians to see target areas and critical structures for every fraction with greater clarity. In Europe and other countries, Elekta Evo continues to gain traction, setting new benchmarks in radiation therapy as more clinics adopt its innovative treatment capabilities.

Ardie Ermers, Executive Vice President, Region Americas, says: “Securing FDA clearance for Elekta Evo is a pivotal step in our commitment to the U.S. market. With Evo, we are empowering American clinics to adopt the latest advances in radiation therapy, delivering more personalized, precise care for their patients. Our strategy is to ensure that every provider, regardless of size or location, can access innovative solutions that improve outcomes and operational efficiency. Evo’s versatility and AI-driven imaging set a new standard for cancer care in the United States.”

Eenas Omari, PhD, a member of the radiation oncology team at Medical College of Wisconsin, which was involved in the development of Iris, says: "Iris provides enhanced image quality. The reduction in artifacts and improved soft tissue contrast not only enhance daily image guidance for precise patient positioning but also allows us to see anatomical changes with greater confidence. This capability maximizes targeting precision and truly personalizes care for each patient."

Unlike conventional cone-beam CT imaging, Evo uses AI to reduce scatter and enhance image reconstruction. This leads to clearer images and helps clinicians see structures more accurately, which supports better decision-making. Iris’s AI-enhanced image quality has been designed to allow for easy upgrading on existing Elekta linacs (dependent on specific linac version; please contact Elekta to learn more).

To learn more, visit the Elekta Evo webpage.
 
*Elekta Evo has CE mark and U.S. FDA 510(k) clearance. Not available in all markets.


Related Content

News | Interventional Radiology

May 12, 2026 — Siemens Healthineers has received clearance from the Food and Drug Administration for six new systems in ...

Time May 12, 2026
arrow
News | Magnetic Resonance Imaging (MRI)

May 11, 2026 – At the International Society for Magnetic Resonance in Medicine (ISMRM) 2026 Annual Meeting, GE ...

Time May 11, 2026
arrow
News | FDA

May 6, 2026 — Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer ...

Time May 07, 2026
arrow
News | Women's Health

May 6, 2026 — GE HealthCare has announced the availability of MIM ComboTherapy GYN HDR/EBRT2, a solution designed to ...

Time May 06, 2026
arrow
News | Magnetic Resonance Imaging (MRI)

April 27, 2026 — SimonMed, one of the nation’s largest independent outpatient imaging providers, has announced the ...

Time May 04, 2026
arrow
News | Radiation Therapy

April 30, 2026 — The Siemens Healthineers business area, Varian, has been awarded up to $60 million over five years by ...

Time April 30, 2026
arrow
News | Computed Tomography (CT)

April 23, 2026 — Royal Philips has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its ...

Time April 30, 2026
arrow
News | X-Ray

April 29, 2026 — Results from a new study* presented at the American Roentgen Ray Society’s (ARRS) 2026 annual meeting ...

Time April 29, 2026
arrow
News | Imaging Software Development

April 28, 2026 — Avatar Medical has been granted FDA 510(k) clearance for Avatar Medical Vision, its software platform ...

Time April 28, 2026
arrow
News | Cardiac Imaging

April 28, 2026 — Abbott has received U.S. Food and Drug Administration (FDA) clearance and CE Mark for its next ...

Time April 28, 2026
arrow
Subscribe Now